Regencell Bioscience Holdings (RGC) Enterprise Value (2022 - 2025)

Regencell Bioscience Holdings (RGC) has reported Enterprise Value for 4 consecutive years, with $270.9 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Enterprise Value changed N/A year-over-year to $270.9 million; the trailing twelve-month figure through Dec 2025 stood at $270.9 million (changed N/A YoY), and the FY2025 full-year result was $216.8 million, up 3283.75% from the prior year.
• Enterprise Value advanced to $270.9 million in Q4 2025 per RGC's latest filing, from $216.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at $270.9 million in Q4 2025 and bottomed at -$6.8 million in Q2 2024.
• Historically, Enterprise Value has averaged $94.5 million across 4 years, with a median of -$3.7 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value sank 83.29% in 2024, then jumped 3283.75% in 2025.
• Over 4 years, Enterprise Value stood at -$4.6 million in 2022, then increased by 18.34% to -$3.7 million in 2023, then tumbled by 83.29% to -$6.8 million in 2024, then jumped by 4077.64% to $270.9 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered $270.9 million, $216.8 million, and -$6.8 million for Q4 2025, Q2 2025, and Q2 2024 respectively.